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Abstract
Background: Non-adherence has been associated with reduced graft survival. The aim of this study was to investigate
the immunological mechanisms underlying chronic renal allograft rejection using a model of non-adherence to
immunosuppressive therapy. We used a MHC (major histocompatibility complex) -mismatched rat model of renal
transplantation (Brown Norway to Lewis), in which rats received daily oral cyclosporine A. In analogy to non-adherence
to therapy, one group received cyclosporine A on alternating days only. Rejection was histologically graded according
to the Banff classification. We quantified fibrosis by trichrome staining and intra-graft infiltration of T cells, B cells, and
monocytes/macrophages by immunohistochemistry. The distribution of B lymphocytes was assessed using
immunofluorescence microscopy. Intra-graft chemokine, chemokine receptor, BAFF (B cell activating factor belonging
to the TNF family), and immunoglobulin G transcription levels were analysed by RT-PCR. Finally, we evaluated
donor-specific antibodies (DSA) and complement-dependent cytotoxicity using flow cytometry.
Results: After 28 days, cellular rejection occurred during non-adherence in 5/6 animals, mixed with humoral
rejection in 3/6 animals. After non-adherence, the number of T lymphocytes were elevated compared to daily
immunosuppression. Monocyte numbers declined over time. Accordingly, lymphocyte chemokine transcription
was significantly increased in the graft, as was the transcription of BAFF, BAFF receptor, and Immunoglobulin
G. Donor specific antibodies were elevated in non-adherence, but did not induce complement-dependent cytotoxicity.
Conclusion: Cellular and humoral rejection, lymphocyte infiltration, and de novo DSA are induced in this model of
non-adherence.
Keywords: Donor specific antibodies, Humoral rejection, Renal transplantation, Non-adherence, Leukocyte infiltration,
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Background
Although short-term renal allograft survival has improved
over the past decades, long-term graft survival is still lim-
ited with overall 5- and 10-year graft survival rates of 77
and 56% respectively in Europe [1]. Research efforts have
therefore focused on identifying ways to prolong graft sur-
vival. A multitude of factors are responsible for chronic
allograft failure, including concomitant disease, calcineurin-
inhibitor (CNI) toxicity, recurrent or de novo renal disease,
as well as chronic allograft rejection [2]. Among these
factors, chronic rejection most frequently causes graft fail-
ure [2, 3]. In this context, subclinical inflammation in renal
allografts [4–6] and the serological appearance of de novo
donor-specific antibodies (dnDSA) have been strongly
implicated as factors for reduced graft survival [3, 7–9]. A
major cause for the formation of de novo DSA is non-
adherence to immunosuppressive therapy [3], and
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numerous studies show that non-adherence itself is a risk
factor for reduced graft survival [10–12].
Antibody mediated rejection (ABMR) is known to be a
major contributor to graft loss [3]. Histologically, the
hallmark feature of chronic antibody mediated rejection
is transplant glomerulopathy (TG), which has been
shown to correlate with the formation of DSA and spe-
cific patterns of C4d deposition [13]. Interstitial fibrosis
and tubular atrophy (IF/TA), though non-specific,
frequently accompany TG in chronic ABMR. Another
histopathological feature, which has been observed in
chronically rejected grafts, are B cell rich tertiary lymph-
oid organs (TLO) [14], which have also been found in
other types of chronically inflamed tissues.
Since dnDSA and ABMR are prominent causes of graft
failure, increasing attention has been drawn to B cells,
due to their function as antibody-producers, as well as
regulatory functions, such as cytokine production. How-
ever, so far B cells have not been specifically targeted by
standard immunosuppressive protocols in renal trans-
plantation, apart from some special applications, such as
ABO-incompatible renal transplantation. Furthermore,
the benefit of B cell depleting agents, such as Rituximab,
in the treatment of ABMR remains controversial [15].
Other B cell targeted therapies have been developed for
chronic inflammatory and autoimmune diseases [16, 17],
but their contribution in allogeneic solid organ trans-
plantation is still under scrutiny.
Previously, we reported on a notable difference in the
relative infiltration of B-lymphocytes in the context of
allogeneic vs. syngeneic transplantation in a rat kidney
transplant model [18]. In the current study, we used a
rat model reflecting non-adherence to immunosuppres-
sive therapy, to answer to following questions: 1.) to
what extent can non-adherence cause rejection 2.) what
effect does non-adherence have on infiltrating leukocyte
populations 3.) how are chemokine transcription pat-
terns affected 4.) how are intra-renal B-cells affected and
5.) does non-adherence result in the development of
donor specific antibodies?
To this end, we used a MHC-mismatched rat model of
allogeneic renal transplantation.
Methods
Animals/experimental renal transplantation
Animal experiments were performed according to Ger-
man animal protection laws and NIH’s laboratory animal
care principles. Study approval was granted by the
inspecting authority (Regierung der Oberpfalz). A MHC-
mismatched rat kidney transplantation model was used,
as previously described [19]. Male Brown Norway rats
(BN) served as donors and male Lewis rats (LEW) as
recipients (Charles River Laboratories, Sulzfeld,
Germany, 200–250 g). Kidney transplantation was either
syngeneic (Lewis-to-Lewis) or allogeneic (Brown-
Norway-to-Lewis).
Kidney transplantation (Tx) was performed as previ-
ously described [19]. In brief, left BN kidneys were
explanted, flushed with cold saline and transplanted
orthotopically in Lewis rats by end-to-end anastomosis
of the ureter and blood vessels. Cold and warm ischemia
times were approximately 35 and 30 min, respectively.
Nephrectomy of the right kidney was performed at the
end of the surgery.
All animals with allogeneic transplantation were
treated with cyclosporine A (CyA 5 mg/kg body weight;
Neoral, Novartis, Basel, Switzerland), administered once
daily by gavage. In one group, CyA was administered
only on alternating days after day 6, in analogy to non-
adherence to immunosuppressive therapy (“Tx d28 CyA
alt.”). Rats were sacrificed 6 and 28 days after transplant-
ation. In general, syngeneic transplantation was used as
a control, except for complement-dependent-cytotoxicity
assay, where Lewis rat serum from day 0 was used.
Groups were abbreviated as follows:
Syngeneic transplantation sacrificed on day 6
(SynTxd6), allogeneic transplantation with daily CyA
sacrificed on day 6 or day 28 (Txd6CyA, Txd28CyA),
and allogeneic transplantation with CyA administered
on alternating days, sacrificed on day 28 (Txd28CyAalt).
Groups consisted of 6 to 11 animals.
Harvested organs were divided into quarters and either
fixed in paraffin or snap-frozen in N2 and stored at
−80 °C, or processed for flow cytometry.
Histology, Immunohistochemistry and
Immunofluorescence
Paraffin sections were prepared from rat kidneys as pre-
viously described [20]. After staining with hematoxylin
and eosin (HE) and periodic acid schiff (PAS) stains, the
histomorphological alterations were classified according
to the Banff classification [21] by an experienced
pathologist.
Immunohistochemistry was performed on 3 μm
formalin-fixed, paraffin-embedded sections as previously
described [18]. Primary antibodies included polyclonal
rabbit anti-rat CD3 antibody (1:100, Abcam, ab5690, Cam-
bridge, UK), polyclonal goat anti-rat CD20 antibody (1:100,
Santa Cruz, sc-7735, Heidelberg, Germany), monoclonal
mouse anti-rat CD68 antibody (1:150, Serotec,
MCA341GA, Oxford, UK), rabbit anti-rat C4d antibody
(Hycultec, HP8034, Beutelsbach, Germany), goat poly-
clonal anti-CCL21 / SLC antibody (aa24–133) (LS-
C150160, Lifespan Biosciences, Seattle, USA), rabbit
monoclonal anti-CCR7 antibody (Y59, ab32527, Abcam,
Cambridge, UK). Secondary antibodies were goat anti-
rabbit-biotin (Dianova, 111–065-144, Hamburg, Germany),
mouse anti-goat-biotin (Dianova, 205–065-108, Hamburg,
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Germany), donkey anti-mouse-biotin (Dianova, 715–065-
150, Hamburg, Germany). Staining was done using DAB
(0.4 mg/ml, Sigma, D5637, St. Louis, USA) and AP-RED
(Zytomed, ZUC001–125, Berlin, Germany). For CCL21
staining, anti-goat-Polymer-HRP Kit (Vector laboratories,
Immpress Reagent Anti-Goat Ig HRP, MP-7405, Peterbor-
ough, UK) was used as a secondary antibody. C4d staining
was enhanced using AP-One-Step Polymer (Zytomed,
ZUC068–006, Berlin, Germany) with Permanent AP RED
Kit (Zytomed, ZUC001–125, Berlin, Germany) as second-
ary antibody. For CCL21 and CCR7, two to three sections
from randomly selected rats from each group were stained.
CD20, CD3, and CD68 staining was analyzed using
Histoquest® software. Digital pictures were taken and 10
high power fields (HPF) per specimen were examined
for analysis (original × 400, covering an area of 296 μm×
222 μm) of each graft as previously described [18]. Using
Histoquest® software, the number of CD68+, CD20+, and
CD3+ cells were counted in relation to all cells within a
defined area. Furthermore, we used immunofluorescence
to better visualize the distribution of CD20+ cell popula-
tion within the grafts on formalin-fixed, paraffin-
embedded materials.
Immunofluorescence staining for CD20 was performed
as previously described [20] on 1–2 randomly selected
sections from each experimental group. Sections (4 μm)
were deparaffinized and rehydrated. Antigen retrieval was
performed in a decloaking chamber (Biocare Medical,
Pacheco, USA) by treatment in citrate buffer and Antigen
Unmasking Solution (Linaris, H-3300, Dossenheim,
Germany). Sections were blocked using Superblock Solu-
tion (Pierce Technology, 37,515, Rockford, USA). The
polyclonal goat anti-rat CD20 antibody (1:100, Santa Cruz,
sc-7735, Heidelberg, Germany) was used at 1:100 in PBS
overnight. After subsequent washing steps, the tissue was
incubated with the donkey anti-goat-FITC antibody (1:500
in PBS, Dianova, 705–095-147, Hamburg, Germany) for
1 h at room temperature. Cell nuclei were stained using
Hoechst 33,342 (Molecular Probes H-1399, Waltham,
USA) 1:50,000 in PBS for 2 min. at room temperature.
Sections were assessed and images taken using a Zeiss ob-
server Z.1 Fluorescence microscope at 20× magnification.
Staining specificity of anti-CD20, anti-CD3, and anti-
CD68 antibodies was confirmed by anatomical staining
pattern of B, and T cells, and monocytes/macrophages re-
spectively in immunofluorescence of rat spleen sections,
showing CD20-positive B cell zones and CD3-positive T
cell zones in splenic follicles, as well as dispersed distribu-
tion of CD68-positive macrophages in the splenic red pulp
(Additional file 1 and Additional file 2). A facs co-stain of
rat monocyte/macrophage marker CD11b/c (mouse anti-
rat CD11b/c-PE, eBiosciences 12–0110-82, San Diego,
USA) and CD68 is also presented in the additional files
section (Additional file 3). T cells were stained using rabbit
anti-rat/hu/ms CD3 (5690, Abcam, Cambridge, UK) and
donkey anti-rabbit-Cy5 (Dianova, 711–175-152) as sec-
ondary antibody (Additional file1) or donkey anti-rabbit-
biotin (Dianova, 711–065-152) and Strep-594 (Dianova,
016–580-084) (Additional file 2). B-cells were stained
using mouse anti-rat CD20 (SantaCruz, sc-393,894) and
goat anti-mouse(IgM)-biotin (ThermoFisher, 31,804) as a
secondary antibody with strep-Cy3 (Dianova, 016–160-
084) (Additional file 1) or using goat anti-rat CD20 (San-
taCruz, sc-7735) and donkey anti-goat-FITC (Dianova,
705–095-147) (Additional file 2). Macrophages were
stained using mouse anti-rat CD68 (BioRad, MCA341GA)
and donkey anti-mouse-DyLight 650 (Abcam, ab98797) as
a secondary antibody.
Flow Cytometry
Rat spleen was mechanically macerated to yield single
cell suspensions for antibody staining and flow cytome-
try. Spleen was coarsely chopped using a scalpel, then
passed through a 70 μm cell strainer, washed, and then
passed through a 30 μm filter. The cell suspension was
further separated using ficoll gradient centrifugation.
The white cell layer (buffy coat) was collected and used
for FACS staining. Cells were blocked using 10% BSA
PBS. The following antibodies were used: mouse anti-rat
CD11b/c-PE (eBiosciences 12–0110-82, San Diego,
USA) and mouse anti-rat CD68 (BioRad, MCA341GA)
with secondary antibody donkey anti-mouse-DyLight
650 (Abcam, ab98797).
Masson Trichrome staining
Renal tissues were fixed in 4% paraformaldehyde and
embedded in paraffin, cut into 4-μm thick sections and
stained with hematoxylin and eosin (HE) and Masson’s
trichrome (MT) staining as follows. First, sections were
deparaffinized and rehydrated by treatment with de-
creasing percentages of ethanol and rinsing in deionized
water. Sections were then treated with Bouin’s solution
containing Pikrin acid, 5% acetic acid and 10% formalde-
hyde overnight and then rinsed. This was followed by
5 min. of Weigerts iron-hematoxylin solution in order to
stain cell nuclei dark blue. Then Bieberich-Scarlet red
acid-fuchsin was applied for 5 min. to stain cytoplasms
red. Phosphorus tungsten and phosphorus molybdenic
acid was applied for 5 min., followed by Anilin blue so-
lution for 15 min., 1 min of 1% acetic acid, and after
rinsing with water, sections were dehydrated using
ethanol treatments in increasing concentrations. The
morphological changes were examined under a Zeiss
Axiostar microscope equipped with a digital camera and
analyzed by Metamorphe software (Metamorph 4.6 Uni-
versal Imaging Corporation). Depending on the size of
the tissue section 10 to 20 images per section (×20 mag-
nification) were captured along the renal cortex, in order
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to calculate the total percentages of the fibrotic areas for
each section.
Real-time PCR
After homogenization of frozen tissue sections using
RNeasy MiniKit® (cat. 74,106, Qiagen, Hilden, Germany)
total RNA was extracted, with additional DNase diges-
tion to remove all traces of genomic DNA. Total RNA
was reverse transcribed into cDNA: cDNA probes were
synthesized in 20 μL reaction volume with 1 μg total
RNA, 0.5 μg oligo(dT) primer (Promega, Mannheim,
Gemany), 40 units of RNasin (Promega, Mannheim,
Germany), 0.5 mM dNTP (Biolabs, Frankfurt am Main,
Germany), 4 μL 5× transcription buffer and 200 units of
Moloney murine leukemia virus (M-MLV) reverse tran-
scriptase (Promega, Mannheim, Germany) for 1 h at 37 °
C. In parallel, no-RT and no-template controls were per-
formed. RT-PCR was performed on ViiA7 detection sys-
tem in triplicates (Applied Biosystems, Darmstadt,
Germany) using QuantiTect SYBR Green PCR Kit
(Qiagen, Hilden, Germany). Hypoxanthine-guanine-
phosphoribosyl-transferase (HPRT) was used as refer-
ence gene. All water controls were negative for target
and housekeeper. The sequences of the primers were:
rHPRT forw: 5’-CTTTGGTCAAGCAGTACAGCC-3′;
rHPRT rev: 5’-TCCGCTGATGACACAAACATGA-3′; r
CCL2 forw: 5’-ATGCAGTTAATGCCCCACTC-3′; rC
CL2 rev: 5’-TTCCTTATTGGGGTCAGCAC-3′; rCCL5
forw: 5’-CTGCCCCTACTTGTCATGGT-3′; rCCL5 rev:
5’-AGATGAGCCTCACAGCCCTA-3′; rCCR5 forw: 5’-
CTATGCCCTTGTTGGGGAGA-3′; rCCR5 rev: 5’-TC
CTGTGGACCGGGTATAGA-3′, rCXCL13 forw: 5’-GC
AAAAATCAGGCTTCCAGA -3′; rCXCL13 rev: 5’-GG
GTCACAGTGCAAAGGAAT-3′; rCCL19 forw: 5’-AG
ACTGCTGCCTGTCTGTGA-3′; rCCL19 rev: 5’-GC
TGGTAGCCCCTTAGTGTG-3′; rCCL20 forw: 5’-CA
ACTTTGACTGCTGCCTCA-3, rCCL20 rev: 5’-CGG
ATCTTTTCGACTTCAGG-3; rCCR7 forw: 5’-GGTC
ATTTTCCAGGTGTGCT-3, rCCR7 rev: 5’-AGTTCCG-
CACATCCTTCTTG-3; rLymphotoxin-β forw: 5’-TAT-
CAC TGTCCTGGCTGTGC-3′, rLymphotoxin-β rev:
5’-GAGATGCACGAGGGTTTGTT-3′; rCCL21 forw:
5’-ACTGCAGGAAGAATCGAGGA-3′; rCCL21 rev: 5’-
TGGACTGTGAACCACTCAGG-3′; rBAFF-R forw: 5’-
GTGGGTCTGGTCAGTCTGGT -3′; rBAFF-R rev: 5’-C
ATTTTCCAGGGACTCTTGG-3′; rBAFF forw: 5’-CT
GGAAACTGCCATGCTTCT-3′; rBAFF rev: 5’-TTC
GTATAGTCGGCGTGTTG-3′; rIgG forw: 5’-CATT
CCCTGCCCCCATC-3′; rIgG rev: 5’-CCGTTCATCTT
CCACTCCGT-3′. rCXCL12 forw: 5’-CTGCCGATTCT
TTGAGAGCC-3′; rCXCL12 rev: 5’-TTCGGGTCAAT
GCACACTTG-3′; rCXCR4 forw: 5′- TCTGAGGCGT
TTGGTGCT-3′; rCXCR4 rev: 5’-CAGACCCTACTTCT
TCGGA-3′. cDNA quantity was determined using a
standard curve. Quantity values of target genes were
normalized to the house-keeping gene HPRT, and x-fold
change of normalized target gene values compared to
syngeneic Tx d6 (used as calibrator) was calculated.
Quantification of donor-specific antibodies (DSA)
Donor (Brown Norway) splenocytes were isolated by
macerating spleen through a 100 μm and 40 μm cell
strainer, followed by ficoll centrifugation and collection
of the white cell layer. Recipient serum was heat-
inactivated (56 °C for 30 min.) in order to disable com-
plement factors. Donor splenocytes were incubated with
recipient serum for 30 min at 4 °C and then washed.
Cells were then stained using either monoclonal mouse
anti-rat IgM-PE (eBioscience, 12–0990, San Diego, USA)
or polyclonal chicken anti-rat IgG-AlexFluor647 anti-
body (Invitrogen/Thermo Fischer, A21472, Waltham,
USA). As positive controls, we incubated donor spleno-
cytes with heat-inactivated goat or rabbit serum and
stained for either goat (donkey anti-goat IgG-DyLight
650, Abcam 96,938, Cambridge, UK) or rabbit (donkey
anti-rabbit IgG-Cy5, Dianova, 711–175-152, Hamburg,
Germany) antibody. Finally, cells were stained for CD3-
FITC (eBioscience 11–0030, San Diego, USA) and mea-
sured by flow cytometry. Data is shown for CD3+-gated
cells, in order to avoid skewing of data by Fc-receptor
binding of non-specific antibodies.
Complement-dependent Cytotoxicity assay (CDC)
Donor splenocytes were isolated as above and resus-
pended in RPMI1640 Medium (Gibco/Thermo Fischer,
Waltham, USA) containing 10% inactivated FCS and
1%Penicillin/Streptomycin. Heat-inactivated recipient
serum and donor splenocytes (200,000 cells/well) were
incubated at 4 °C for 30 min. Rabbit complement (BAG
7018, Lich, Germany) was added and incubated for 2 h
at 24 °C. Goat (DAKO X0907, Hamburg, Germany) or
rabbit (DAKO X0902, Hamburg, Germany) serum were
used as positive control. Cells were washed and stained
with propidium iodide (PI) (Invitrogen/Thermo Fischer,
Waltham, USA) to distinguish dead cells and then mea-
sured by flow cytometry. Complete lysis was measured
using FixPerm (Thermo Fischer, Waltham, USA). Per-
cent cytotoxicity was calculated using the formula: (“PI
+cells in sample” – “PI+cells in medium”)/(“PI+cells in
FixPerm” – “PI+cells in Medium”) ×100.
Statistical analysis
Values are provided as mean ± SEM. Statistical analysis
was performed by the non-parametric Mann-Whitney
U-test. p < 0.05 was considered to be statistically
significant.
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Results
Pronounced rejection and acceleration of chronic
interstitial damage under conditions simulating non-
adherence
Syngeneic transplantation did not lead to any relevant
histological changes (Table 1). Allogeneic transplantation
lead to mixed cellular and humoral rejection at day 6
(Txd6CyA). In this group, cellular rejection occurred
primarily in the form of tubulitis (Table 1), although 1/
11 allografts also had signs of vascular rejection (Banff
class 4 IIA). Ten of 11 grafts from this group showed
specific features of humoral rejection, including discrete
to moderate peritubular capillaritis and C4d-positive
staining along peritubular capillaries (Table 1, Fig. 1a-b).
After continued daily immunosuppression until day 28
(Txd28CyA), 3/6 grafts showed normal histology, but 3/
6 grafts still showed cellular rejection with beginning
endothelialitis and predominantly perivascular infiltrates,
but without signs of additional humoral rejection
(Table 1, Fig. 1c-d). When cyclosporine was only admin-
istered on alternating days simulating non-adherence
(Txd28CyAalt.), graft histology showed moderate cellular
rejection in 5/6 grafts, with endothelialitis and perivas-
cular infiltrates, and 3/6 grafts from this group also
showed signs of humoral rejection with ongoing peritubu-
lar capillaritis, but negative C4d staining (Table 1, Fig. 1e-
f). In addition, trichrome staining showed a significant in-
crease of interstitial fibrosis in the non-adherent group in
comparison to the adherent group as shown in Fig. 2a-c
(Txd28CyA vs. Txd28CyAalt. p = 0.0043) demonstrating
an acceleration of chronic interstitial changes induced by
intermittent immunosuppression.
Infiltration of inflammatory cell populations
Immunohistochemical staining of CD3, CD68, and CD20
in kidney sections showed that, as expected, allogeneic
transplantation led to a significant infiltration of CD68+
monocytes/macrophages, and CD3+ and CD20+ lympho-
cytes by day 6 when compared to syngeneic transplant-
ation (Fig. 3 a-c). When daily cyclosporine treatment was
continued until day 28 (Txd28CyA), intra-renal infiltration
of all 3 cell populations was strongly reduced in compari-
son to day 6 after allogeneic transplantation (CD3 p =
0.004, CD20 p = 0.06, CD68 p = 0.002). However, after
simulation of “non-adherence” (Txd28CyAalt.), strong
CD3+ cell infiltration was sustained (p = 0.0047 for CD3+
cell infiltration in TxCyAd28 vs. Txd28CyAalt.). CD20+
cell infiltration in non-adherence was similar to infiltra-
tion after daily immunosuppression, but was significantly
elevated compared to syngeneic transplantation. Mono-
cyte/macrophage numbers were as low after non-adher-
ence as after syngeneic transplantation.
Distribution of B cells in clusters after non-adherence
Although the total number of intra-renal CD20+ B lym-
phocytes only showed a slight increase after non-
adherence compared to daily immunosuppression, which
did not reach statistical significance at this group size,
analysis of B cell distribution by immunofluorescent
staining showed a remarkable trend towards more orga-
nized clusters of B cells. As shown in representative sec-
tions in Fig. 4, infiltrating CD20+ cells are randomly
scattered in allograft tissue at day 6 (Fig. 4a) and moved
into a distinctly grouped distribution after continued
daily immunosuppression until day 28 (Fig. 4b). When
immunosuppression was intermittently omitted in ana-
logy to non-adherence, B cells formed dense clusters as
shown in Fig. 4c. Fully matured tertiary lymphoid folli-
cles were not observed at this time-point.
Chemokines recruit adaptive immunity during non-
adherence
Intra-graft chemokine transcription was compared to infil-
trating leukocyte populations. Fittingly, a strong induction
of chemokines attracting lymphocytes (CCL19/CCL20/
CCL21/Lymphotoxin-β/CCL5), rather than monocytes
(CCL2), was seen under conditions simulating non-
adherence (Fig. 5); p-values for the difference in “non-ad-
herence” compared to standard immunosuppression at
day 28 were: p = 0.009 for CCL19, p = 0.03 for CCL20, p =
0.019 for CCL21, p = 0.004 for Lymphotoxin-β, p = 0.03
for CCL5, and p = 0.90 for CCL2. However, an induction
of corresponding chemokine receptors CCR7 (CCL19/
CCL21 receptor) and CCR5 (CCL5 receptor) was not ob-
served after “non-adherence” (Fig. 5). However, immuno-
histochemical staining of CCR7 of renal allograft sections
revealed positive staining of leukocyte infiltrates, and this
was increased in the groups Txd6CyA and Txd28CyAalt.
Table 1 Histopathological classification of allograft rejection in analogy to the Banff classification. Group sizes ranged from 6 to 11
rats per group
Group No
rejection
Class 2 I-II
C4d-positive
Class 2 I-II
C4d-negative
Class 4
IA
Class 4
IB
Class 4
IIA
Class 4
IIB
Mixed
Rejection
Syn Tx d6 (n = 8) 8
Tx d6 CyA (n = 11) 10 2 8 1 10
Tx d28 CyA (n = 6) 3 3
Tx d28 CyA alt. (n = 6) 1 3 5 3
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(Fig. 6) compared to synTxd6 and Txd28CyA. In the non-
adherence group CCR7-staining of infiltrates was more
pronounced than in infiltrates from group Txd6CyA. Not-
ably, tubular epithelial cells were also CCR7-positive, which
has previously been reported in the context of renal trans-
plantation [22]. Overall, the intensity of CCR7 staining
reflected the pattern of mRNA expression in the different
experimental groups. Interestingly, transcription of CCL19,
CCL20, and CCL21 was not induced early after transplant-
ation (day 6), but strongly induced after a period of “non-
adherence” (Txd6CyA vs. Txd28CyAalt: p = 0.0001 for
CCL19, p = 0.005 for CCL20, p = 0.008 for CCL21, Fig. 5).
In order to confirm mRNA expression on a protein level,
immunohistochemical staining of CCL21 was performed
in 2–3 randomly selected allograft sections from each
group (Fig. 7). The intensity of CCL21 staining correlated
well with PCR data, where expression was low in all groups
except the non-adherence group (Fig. 7d). Here, strong
CCL21 expression was localized in areas of lymphocyte
infiltration. Transcription of the B cell specific chemokine
CXCL13 was not significantly induced after “non-
a b
c d
e f
Fig. 1 a-f Representative renal allograft sections are shown from each group of transplanted rats (n = 6–11) (a-b) Txd6CyA (c-d) Txd28CyA, and
(e-f) Txd28CyAalt. The left shows hematoxylin & eosin staining with arrows showing peritubular capillaritis. The right shows anti-rat C4d staining
(brown) with arrows pointing out dilated peritubular capillaries containing marginated mononuclear cells and neutrophils and C4d-positivity and
black circles showing negative anti-rat C4d staining in peritubular capillaries
Tx
 d
28
 C
yA
Tx
 d
28
 C
yA
 al
t.
0.0
0.5
1.0
1.5
2.0
Tr
ic
h
ro
m
e 
p
o
si
tiv
e 
ar
ea
 (%
)
*
a
b
c
Fig. 2 a-c Trichrome staining was used to quantify interstitial fibrosis.
Representative sections are shown (a) Txd28CyA and (b) Txd28Cyalt. In
(c) quantitative analysis of percent trichrome positive area is shown. 6
rats per group were analyzed. The mean and standard error is shown.
Significance (Mann-Whitney U Test) is shown as * p < 0.05 compared
to “Txd28CyAalt”
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adherence”. CXCL12 and its receptor CXCR4 represent an
important axis for migration of T, B, and plasma cells, as
well as dendritic cells [23], and have been shown to induce
dendritic cell rich TLOs in mice [24], however the mRNA
expression of CXCR4 and CXCL12 was relatively low.
Intra-graft CXCR4 expression was increased in Txd6CyA,
but no other group compared to syngeneic Tx d6 (Add-
itional file 4). CXCL12 expression was low and did not dif-
fer in the different experimental groups (Additional file 4).
Non-adherence increases intra-renal B cell activating
factor (BAFF) and IgG transcription
Intra-graft BAFF (B cell activating factor belonging to the
TNF family) transcription is induced early after allogeneic
transplantation (p = 0.0003 for Txd6CyA vs. SynTxd6) and
is additionally significantly increased in non-adherence
compared to standard immunosuppression at day 28 (p =
0.026 for Txd28CyAalt. vs. Txd28CyA, Fig. 8a). BAFF-
receptor transcription levels are also significantly increased
after non-adherence (p = 0.0007 compared to control n = 6,
Fig. 8b). A significant rise of intra-graft Immunoglobulin G
(IgG) transcription was observed in the non-adherence
group in comparison to all other groups (Txd28CyAalt. vs.
Txd28CyA p = 0.004, vs. Txd6 p = 0.0028, vs. SynTxd6 p =
0.0007, Fig. 8c).
Development of de novo donor-specific antibodies
To test for DSA, recipient serum was incubated with
donor splenocytes and stained for rat IgM (immuno-
globulin M) and IgG (immunoglobulin G). Goat and
rabbit serum were expected to contain xenoantibodies
and were used as positive controls showing robust and
titratable positive signals for the anti-rat IgG and IgM
FACS stain (data not shown) and also complement-
dependent cytotoxicity (Fig. 10a). Recipient sera after
syngeneic transplantation did not show positive anti-rat
IgG or IgM staining on donor splenocytes (Fig. 9a-b).
However, allogeneic transplantation led to the appear-
ance of high levels of donor-specific IgM and IgG early
after transplantation (day 6) (p = 0.004 for Txd6CyA vs.
SynTxd6 for IgM and p = 0.002 for IgG). As expected,
donor-specific IgM disappeared by day 28 (Fig. 9a). IgG
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Fig. 3 a-c Immunohistochemistry was performed on rat kidneys after syngeneic or allogeneic transplantation treated with CyA for 6 or 28 days,
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a b c
Fig. 4 a-c Immunofluorescent staining of CD20 in renal allograft was performed. Representative sections from Txd6CyA (a), Tx28CyA (b), and
Txd28CyAalt. (c) are shown. Anti-CD20 was labeled with a fitc-conjugated secondary antibody (bright green)
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levels also markedly decreased by day 28 under daily im-
munosuppression in 3/6 subjects, but remained elevated in
another 3/6 (Fig. 9b, Txd28CyA). A highly relevant obser-
vation was, that the same 3/6 rats from the group showing
virtually no DSA also lacked histological signs of rejection;
in contrast, the remaining 3/6 rats which did show histo-
logical signs of rejection (Table 1), also displayed measur-
able amounts of DSA in serum. In the non-adherence
group, donor-specific IgG was elevated in all measured
samples (p = 0.004 for SynTxd6 vs. Txd28CyAalt.), and this
corresponded with histological signs of C4d-negative
ABMR in 3/6 animals in this group.
In order to rule out any binding of non-specific immu-
noglobulins, we incubated recipient sera, which had pre-
viously shown IgG-binding on donor splenocytes
(Txd6CyA) with recipient Lewis rat splenocytes (data
not shown). There was no staining of rat-IgG or IgM on
Lewis splenocytes, confirming that the observed anti-rat
IgG are donor-specific. Similarly, Lewis rat serum from
day 0 did not show any specific binding of anti-rat IgG
on BN splenocytes (data not shown).
Using a complement-dependent cytotoxicity assay,
we found that only DSA produced early after trans-
plantation (Txd6CyA) activated complement-mediated
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Fig. 5 a-i Quantitative RT-PCR analysis of chemokine and chemokine receptor expression from renal grafts after syngeneic or allogeneic transplantation
treated with CyA for 6 or 28 days, or CyA on alternating days until d28. mRNA expression of target genes was normalized to the house-keeping gene
HPRT and x-fold expression in comparison to syngeneic Tx d6 is shown. In (a) CCL19, (b) CCL20, (c) CCL21, (d) Lymphotoxin-β, (e) CCL5, (f) CXCL13, (g)
CCL2, (h) CCR7, and (i) CCR5. Data is shown as mean ± SEM. Groups consisted of at least 6 animals. Statistical analysis is shown (Mann-Whitney U Test).
Significance is shown as *p< 0.05 compared to “SynTxd6”, and # p < 0.05 compared to “Txd28CyAalt”
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cytotoxicity (CDC) (Fig. 10, p = 0.03 for Txd6CyA vs.
Lewis Serum d0), while no cytotoxicity was observed
after 28 days of daily or alternating CyA treatment,
(p = 0.03 for Txd6CyA vs. Txd28CyAalt.), eventhough
DSA were detected in this group by flow cytometry
(Fig. 9b). These results are consistent with the pattern
of C4d-staining in the different groups, which showed
positive C4d staining at day 6 after allogeneic Tx, but
not at day 28 after daily or intermittent immunosup-
pression (Fig. 1).
Discussion
Since non-adherence to immunosuppressive therapy is
strongly associated with donor-specific antibodies and
accelerated graft failure, our aim was to utilize a rat
model of non-adherence in order to study the immuno-
logical mechanisms underlying chronic allograft injury.
In our model, MHC-mismatched rat strains were used
for allogeneic renal transplantation. Acute humoral and
cellular rejection was observed at day 6. As the animals
were not pre-sensitized, the immunological risk was
a b
c d
Fig. 6 a-d CCR-7 expression in renal allografts. Two to three randomly selected sections per group were stained with anti-CCR7 antibody. Repre-
sentative sections are shown. (a) synTxd6 (b) Txd6CyA (c) Txd28CyA and (d) Txd28CyAalt
a b
c d
Fig. 7 a-d CCL21 expression in renal allografts. Two to three randomly selected sections per group were stained with anti-CCL21 antibody. Representative
sections are shown. (a) synTxd6 (b) Txd6CyA (c) Txd28CyA and (d) Txd28CyAalt
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considered low, and no induction therapy was used.
When immunosuppression was continued, rejection
subsided in some animals, but not all, probably because
the dose of cyclosporine used (5 mg/kg) was relatively
low and no induction therapy or steroid was adminis-
tered on top. Under daily cyclosporine administration,
normal histology or mild cellular rejection was seen at
day 28. In contrast, the non-adherence group suffered
from a significant increase in the rate of cellular rejec-
tion with additional features of acute humoral rejection
– illustrated by initiation of peritubular capillaritis. Our
model intended to show mechanisms of early chronic
parenchymal changes. Such changes were indeed in-
duced in our model of non-adherence, as demonstrated
by a significant increase in interstitial fibrosis.
While cellular infiltration was minimal after syngeneic
transplantation, high numbers of inflammatory cells
were seen early after allogeneic transplantation (day 6)
with monocytes dominating the infiltrate. The numbers
of monocytes, T cells and B cells declined when standard
immunosuppression with daily CyA was continued.
However, under conditions simulating non-adherence, T
cell infiltration did not resolve as quickly as under daily
immunosuppression. Meanwhile, B cell numbers
remained elevated in comparison to syngeneic trans-
plantation and monocyte numbers declined to a level
similar to that after syngeneic transplantation. In line
with these results, Hueso et al. previously showed that
early interstitial fibrosis/tubular atrophy (IF/TA) and re-
duced graft survival are associated with increased
a b c
Fig. 8 a-c Quantitative RT-PCR analysis of BAFF, BAFF receptor and IgG expression from renal grafts after syngeneic or allogeneic transplantation
treated with daily CyA for 6 or 28 days, or CyA on alternating days until d28. mRNA expression of target genes was normalized to the
house-keeping gene HPRT and x-fold expression in comparison to syngeneic Tx d6 is shown. In (a) BAFF, (b) BAFF-Receptor, and (c) IgG.
Data is shown as mean ± SEM. Groups consisted of at least 6 animals. Statistical analysis is shown (Mann-Whitney U Test). Significance is
shown as * p < 0.05 compared to “SynTxd6”, and # p < 0.05 compared to “Txd28CyAalt”
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Fig. 9 a-b Detection of donor-specific antibodies from rats after syngeneic or allogeneic kidney transplantation treated with daily CyA for 6 or
28 days, or CyA on alternating days until d28. Donor splenocytes were incubated with recipient serum and then stained with (a) anti-rat IgM-antibody
or (b) anti-rat IgG-antibody in duplicates and measured by flow cytometry. Percentages of IgG or IgM-positive cells are shown. Data is shown as single
data points of each group on a scatter plot. Groups consisted of 5–6 animals. Statistical analysis is shown (Mann-Whitney U Test). Significance is shown
as * p < 0.05 compared to “SynTxd6”, # p < 0.05 compared to “Txd28CyAalt”
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infiltration of T and B cells in human renal transplant
biopsies [25].
The changes seen in the pattern of intra-renal chemo-
kine transcription mirrored the changes in the compos-
ition of the cellular infiltrate, with chemokines attracting
T and B lymphocytes, such as CCL19, CCL20, CCL21,
CCL5 and lymphotoxin-β, increased in non-adherence.
Interestingly, CCL19, CCL20, and CCL21, were much
more strongly induced in the setting of non-adherence
than during the initial inflammatory reaction early after
Tx (d6). CCL19, CCL21, and their receptor CCR7 are
known to regulate homing and co-localization of den-
dritic cells and naïve T cells in lymphoid organs and are
essential to T cell sensitization and the formation of an
adaptive immune response [26]. However, they have also
been implicated in the formation of tertiary lymphoid
organs (TLO) in the context of chronic inflammation
[24, 27, 28]. These structures have also been found in
transplant organs and are associated with a poorer out-
come [14, 29]. In a murine model of kidney transplant-
ation, the fusion protein CCL19-IgG, which interferes
with normal CCL19-CCR7 signaling, was found to
strongly reduce graft rejection [30]. In our model of
non-adherence, chemokines associated with TLO forma-
tion are strongly expressed, and this is accompanied
with the formation of dense lymphocyte aggregates.
Another factor that has been associated with chronic in-
flammation and formation of B cell rich TLO is B cell acti-
vating factor (BAFF) [31]. BAFF is an activation,
maturation and survival factor for B cells, expressed by
lymph node stromal cells, neutrophils, macrophages,
monocytes, dendritic cells and T cells [32]. A pathogenetic
role for BAFF has been suggested for several autoimmune
diseases, including Sjögren Syndrome, systemic lupus ery-
thematosus, and multiple sclerosis [33–35]. In the context
of renal transplantation, higher serum levels of BAFF are
associated with donor-specific antibodies [36], blood cell-
bound BAFF with worse renal graft function, and intra-
graft BAFF expression is associated with ABMR and IF/
TA [37]. We now show that BAFF transcription is in-
creased within the graft during non-adherence. In line
with this, IgG transcription levels are also increased dur-
ing non-adherence. In fact, the non-adherence group was
the only group that showed intra-renal IgG transcription,
demonstrating that local intra-graft antibody formation
exclusively occurred after prolonged suboptimal
immunosuppression.
Although, fully developed TLO structures were not yet
observed in our experimental setting at the analyzed
time-points, the enhanced organization of B lympho-
cytes into dense clusters during our simulation of non-
adherence together with the increased expression of
a c
b
Propidium Iodide
Fig. 10 Complement-dependent-cytotoxicity of donor-specific antibodies from rats after syngeneic or allogeneic kidney transplantation treated
with daily CyA for 6 or 28 days, or CyA on alternating days until d28. Donor splenocytes were incubated with recipient serum and rabbit comple-
ment. Dead cells were stained with propidium iodide (PI) and measured by flow cytometry. (a) shows representative histograms of PI-staining for
negative control (cell medium, shown in red) and positive controls (Fix/perm, shown in blue; goat serum shown in green; rabbit serum shown in
orange). (b) shows representative histograms of PI-staining for control (Lew d0), Txd6CyA, Txd28CyA, and Txd28CyAalt. (c) shows quantitative ana-
lysis as percent lysis (n = 3–4 per group). Significance (Mann-Whitney U Test) is shown as * p < 0.05 compared to control (Lewis rat serum pre-Tx
d0), # p < 0.05 compared to “Txd28CyAalt”
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TLO-associated chemokines CCL19, CCL20, CCL21,
and BAFF may be indicative of early steps in the forma-
tion of these highly organized structures. Furthermore,
the appearance of intra-graft IgG transcription maybe
linked to the development of an organized local adaptive
immune response. Although our experiments cannot
differentiate plasma cell infiltration from local differenti-
ation from precursor cells, a possible explanation maybe
that BAFF activates intra-renal B cells, which mature
into antibody-secreting plasma cells within the graft.
Similarly, our experiments cannot rule out that
increased IgG transcription is due to turnover of local B
cell populations in non-adherence, but evidence for local
antibody production by plasma cells in chronic rejection
has been provided by Thaunat et al. [14]. There is also
evidence for clonal expansion of B cells inside grafts
[38]. No conclusions can be drawn as to the specificity
or diversity of the IgG produced in our non-adherence
model, and further experiments will be needed to estab-
lish the source and specificity of intra-graft IgG produc-
tion. Others have shown however, that locally and
systemically produced antibodies differ in diversity and
timing with more diverse HLA (human leukocyte
antigen) specificities being generated from intra-graft
antibody production [14, 39].
In our model, de novo DSA were detected in rat
serum under conditions mimicking non-adherence to
therapy. This corresponds to data from studies of
renal transplant patients [3, 10, 11]. Antibodies were
shown to be donor-specific, since binding of recipient
Lewis rat splenocytes did not occur. Although our ex-
periments could not specifically identify anti-MHC
antibodies, endothelial non-MHC targets for these
antibodies were unlikely since splenocytes were used
in our assay. IgM and IgG DSA were detected early
after transplantation (day 6), following a kinetic previ-
ously described for rat humoral responses after
immunization [40, 41]. At the later timepoint, we saw
a clear induction of a secondary humoral response,
where IgM was no longer detected, while IgG levels
remained elevated. We interpreted this as a sign that
Ig class switching was completed, and that
sensitization to donor antigens and initial DSA pro-
duction takes place very early. Our results suggest
that activated B cells and plasma cells are then armed
and ready for antibody production, and are kept in
check by appropriate immunosuppression with CNI.
Analysis of CDC showed that DSA were cytotoxic
early after Tx (d6), but not after non-adherence or
daily CyA (d28), which was consistent with the pat-
tern of C4d-staining observed in the different groups.
Our experiments do not offer a specific mechanism
to explain this phenomenon, but one possibility is
that the different immunosuppressive treatments and
durations result in a switch in the IgG-subclass gen-
erated and thereby also determine the phenotype of
ABMR, eg. C4d-positive vs. C4d-negative, in line with
recently published observations of DSA IgG sub-
classes and rejection phenotypes in transplant patients
[42]. In this study of renal transplant patients, chronic
ABMR was associated with the non-complement acti-
vating IgG subclass IgG4 in humans, whereas acute
ABMR was associated with the complement-fixing
IgG3 [42].
Under-immunosuppression in a clinical setting may be
due to non-adherence to therapy or to inter-individual
variations in responsiveness to CNI, since CNI therapy
is monitored using serum concentration, not functional
tests. Considering this, even when optimal adherence to
therapy is achieved, a group of patients may still effect-
ively be “under-immunosuppressed” and at risk of
chronic rejection.
While there is a lot of data showing the deleterious
effects of DSA on graft outcome, there is an ongoing
debate over which DSA are clinically relevant, or
more precisely, what features of DSA, such as MFI
(mean fluorescence intensity), complement-fixing
capacity or IgG-subclass, are linked to deleterious
outcomes and require treatment [42–44]. Our model
offers an ideal framework for deciphering such critical
issues.
Several animal models have been established in which
preformed DSA are induced using pre-transplant
immunization [45, 46]. Since in the majority of cases,
DSA are de novo DSA and not DSA from pre-
sensitization, our model - with reliable histological and
serological entities of acute antibody mediated rejection
during non-adherence - more closely resembles this
highly prevalent group of patients.
Conclusion
In this study, we established and characterized a rat
model of CNI under-immunosuppression in analogy
to non-adherence to immunosuppressive therapy after
allogeneic kidney transplantation. In this model, non-
adherence led to mixed cellular and humoral
rejections. This study shows that during prolonged
under-immunosuppression, lymphocytic infiltrates take
up an organized form within the graft. This is pro-
moted by factors also associated with formation of
secondary and tertiary lymphoid organs. Furthermore,
intra-renal IgG mRNA synthesis was induced after
prolonged under-immunosuppression. These intra-
renal changes are accompanied by systemic produc-
tion of donor-specific antibodies after non-adherence.
The contribution of organized lymphocytic infiltrates
to chronic allograft injury needs to be addressed in
further studies.
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Additional file 1: anti-CD20 and anti-CD3 immunofluorescence costaining
of rat spleen follicles. Anti-CD20-positive B cells are in the B cell zone of
splenic follicles (yellow), and anti-CD3-positive T cells in the T cell zone of
the splenic follicles (red), also shown are proliferating Ki67-positive cells in
splenic follicles (green). (PDF 3198 kb)
Additional file 2: anti-CD20, anti-CD3, and anti-CD68 immunofluorescence
costaining of rat spleen follicle. (A) shows anti-CD20-positive B cells in the B
cell zone of a splenic follicle (green), anti-CD3-positive T cells in T cell
zone of splenic follicle (red), and CD68-positive macrophages (yellow) in
the splenic red pulp, also shown in (B) without costaining. (PDF 588 kb)
Additional file 3: anti-CD11b/c and anti-CD68 FACS costain of rat spleno-
cytes. (A) shows unstained cells, (B) shows anti-CD11b/c-PE antibody only,
and (C) shows anti-anti-CD11b/c-PE antibody and anti-CD68-APC anti-
body co-stain of rat splenocytes. (PDF 82 kb)
Additional file 4: CXCR4 and CXCL12 expression. This figure shows
quantitative RT-PCR analysis of chemokine and chemokine receptor expression
from renal grafts after syngeneic or allogeneic transplantation treated with
CyA for 6 or 28 days, or CyA on alternating days until d28. mRNA expression
of target genes was normalized to the house-keeping gene HPRT and x-fold
expression in comparison to syngeneic Tx d6 is shown. (A) CXCR4 (B) CXCL12.
Data is shown as mean± SEM. Groups consisted of at least 6 animals. Statistical
analysis is shown (Mann-Whitney U Test). Significance is shown as *p< 0.05
compared to “SynTxd6”, and # p < 0.05 compared to “Txd28CyAalt”. (PDF 24 kb)
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